Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of
the Securities
Exchange Act of 1934
Date of Report
(Date of earliest event reported): April 23, 2018
AZURRX
BIOPHARMA, INC.
(Exact
name of Registrant as specified in its Charter)
|
Delaware
|
001-37853
|
46-4993860
|
|
(State or Other
Jurisdiction of
Incorporation or
Organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:(646)
699-7855
(Name, address,
including zip code, and telephone number, including area code, of
agent for service of process)
NOT APPLICABLE
(Former Name or
Former Address, if Changes Since Last Report)
Check the
appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions):
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2) ☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act ☐
|
Item
8.01
|
Other Events
|
On April 23, 2018, AzurRx BioPharma, Inc. (the
“Company”) announced
additional positive interim data results for its ongoing Phase IIA
trial of MS1819-SD, a recombinant lipase, for the treatment of
exocrine pancreatic insufficiency caused by chronic
pancreatitis. A
copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K, and is incorporated by
reference herein.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AzurRx BioPharma,
Inc.
|
|
|
|
|
|
|
|
|
Date:
April
23, 2018
|
By:
|
/s/ Johan M.
Spoor
|
|
|
|
|
Name: Johan M. Spoor
|
|
|
|
|
Title: Chief Executive Officer
|
|
|
|
Exhibit
Index
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
Press Release dated
April 23, 2018
|
|